Issues in the utilization of low molecular weight heparins

Seminars in Hematology

Volumn 39, Issue 3, 2002, Pages 172-178

  O'Shea, Susan I ^a   Ortel, Thomas L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; CANCER; DELIVERY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; EPIDURAL ANESTHESIA; HEART VALVE PROSTHESIS; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; OBESITY; PATIENT MONITORING; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; THROMBOEMBOLISM; DRUG CONTRAINDICATION; DRUG MONITORING; FEMALE; MALE;

ANTICOAGULANTS; DRUG MONITORING; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; PREGNANCY;

EID: 0035992699     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2002.34090     Document Type: Article

References (78)

1. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies
2. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, antiactivities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery
3. Heparin-induced thrombocytopenia presenting after the cessation of low molecular weight heparin prophylaxis with enoxaparin
4. Pharmacodynamics (PD) of the low molecular weight heparin, tinzaparin, in obese volunteers
5. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit
6. The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease
7. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin
8. Delayed elimination of enoxaparin in patients with chronic renal insufficiency
9. Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY 216) in normal and nephrectomized rabbits
10. Anticoagulation of pregnant women with mechanical heart valves: A systematic review of the literature
11. Antithrombotic therapy during pregnancy
12. Heparin-induced thrombocytopenia: Association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation
13. Low-molecular-weight heparins in non-ST-segment elevation ischemia: The ESSENCE trial
14. A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement
15. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial
16. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study
17. Low-molecular-weight heparin during pregnancy and delivery: Preliminary experience with 41 pregnancies
18. Outpatient treatment of deep vein thrombosis: Translating clinical trials into practice
19. Dosing and monitoring of low-molecular-weight heparins in special populations
20. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery
21. Are the available low-molecular-weight heparin preparations the same?
22. Placental transport of heparin
23. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: Study by direct fetal blood sampling under ultrasound
24. Enoxaparin and bleeding complications: A review in patients with and without renal insufficiency
25. Use of antithrombotic agents during pregnancy
26. Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure
27. Low molecular weight heparin half life is prolonged in haemodialysed patients
28. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials
29. A population-based pharmacokinetic study of enoxaparin in obese patients with acute coronary syndrome
30. Hypercoagulability in cancer
31. Heparin-associated thrombocytopenia: The antibody is not heparin specific
32. Pharmacodynamics of the LMWH, tinzaparin, in renal failure patients following IV and SC administration
33. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
34. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers
35. Low molecular weight heparin and neuraxial anesthesia
36. Pharmacokinetics of a very low molecular weight heparin in chronic renal failure
37. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis
38. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies
39. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4
40. Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?
41. Pharmacokinetics of low-molecular-weight heparin and unfractionated heparin during elective aortobifemoral bypass grafting
42. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy. The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban
43. Low molecular weight heparin and ASA therapy in women with autoantibodies and unexplained recurrent fetal loss (U-RFL)
44. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy
45. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran (Org 10172)
46. Heparin-induced thrombocytopenia after elective hip joint replacement with postoperative prevention of thromboembolism with low-molecular-weight heparin
47. The effect of bolus injection of unfractionated or low molecular weight heparin during aortobifemoral bypass grafting
48. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease
49. Orgaran (Org 10172): Its pharmacological profile in experimental models
50. Antithrombotic therapy in children
51. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin)
52. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats
53. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: A report on 48 cases
54. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy
55. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance
56. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy
57. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: Clinical implications for heparin-induced thrombocytopenia
58. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
59. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)
60. The use of low-molecular weight heparins in heparin-induced thrombocytopenia (HIT): A cohort study
61. Abnormal platelet function in haemodialysed patients: Current concepts
62. Low-molecular-weight heparin vs. unfractionated heparin in femorodistal reconstructive surgery: A multicenter open randomized study
63. Safety of low- molecular-weight heparin in pregnancy: A systematic review
64. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
65. Low molecular mass heparin instead of unfractionated heparin during infrainguinal bypass surgery
66. The Columbus Investigators: Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
67. Venous thromboembolism during pregnancy: A current review of diagnosis and management
68. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomized trial
69. Low-molecular-weight heparin in the management of Trousseau's syndrome
70. A 14-year study of heparin-induced thrombocytopenia
71. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
72. Impact of the patient population on the risk for heparin-induced thrombocytopenia
73. Low-molecular-weight heparins
74. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism
75. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man
76. Regional anesthesia and anticoagulation